The surgeons used the Inspiris Resilia artificial valve, a technology developed by California-based Edwards Lifesciences Corp. and recently approved by the U.S. Food and Drug Administration.

Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra ...

The Inspiris valve is a new implant for patients with aortic valve disease, which doctors think may help prevent future open heart surgeries. Skip Navigation.

Today, RESILIA tissue is used in a wide range of Edwards’ surgical and transcatheter platforms, including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve ...

“Given that TAVR is mounted on a flexible stent, unlike Inspiris with Resilia tissue mounted on a rigid surgical valve frame, we will need to determine the long-term outcomes of Resilia in a ...

The Inspiris Resilia Aortic valve which is an artificial biological valve is also a tri-leaflet valve made from cow’s heart tissue and specially purified with special agents to resist or ...

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative ...

Today, RESILIA tissue is used in a wide range of Edwards’ surgical and transcatheter platforms, including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve ...